Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762

2016 European Guidelines on cardiovascular disease prevention in clinical practice

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457

Fourth universal definition of myocardial infarction (2018)

Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., ESC Scientific Document Group, Thygesen, K., Alpert, J. S., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy462 · Cited by 5,880

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308

Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays

Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900428 · Cited by 1,687

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271

Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations

Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083

Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea

Mueller, C., Scholer, A., Laule-Kilian, K., Martina, B., Schindler, C., Buser, P., Pfisterer, M., & Perruchoud, A. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031681 · Cited by 1,000

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942

B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study

McCullough, P. A., Nowak, R. M., McCord, J., Hollander, J. E., Herrmann, H. C., Steg, P. G., Duc, P., Westheim, A., Omland, T., Knudsen, C. W., et al. (2002) · Circulation · doi:10.1161/01.cir.0000025242.79963.4c · Cited by 879

Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays

Apple, F. S., Collinson, P. O., & for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.165795 · Cited by 861

State of the art: using natriuretic peptide levels in clinical practice

Maisel, A., Mueller, C., Adams, K., Anker, S. D., Aspromonte, N., Cleland, J. G. F., Cohen-Solal, A., Dahlstrom, U., DeMaria, A., Di Somma, S., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.014 · Cited by 839

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1920 · Cited by 815

Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab

Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814

Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations

Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J. G. F., Kozhuharov, N., Coats, A. J. S., Metra, M., Mebazaa, A., Ruschitzka, F., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1494 · Cited by 804

Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients

Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 682

Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial

Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., Patle, A., et al. (2013) · JAMA · doi:10.1001/jama.2013.7588 · Cited by 664

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615

Molecular mechanism of doxorubicin-induced cardiomyopathy – An update

Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588

Immune checkpoint inhibitors and cardiovascular toxicity

Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J. E., Shankar, S., Sieswerda, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70409-7 · Cited by 570

Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab

Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity

Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J.-J., Scemama, U., Jacquier, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030571 · Cited by 517

High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study

Shah, A. S. V., Anand, A., Sandoval, Y., Lee, K. K., Smith, S. W., Adamson, P. D., Chapman, A. R., Langdon, T., Sandeman, D., Vaswani, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00391-8 · Cited by 510

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

Avila, M. S., Ayub-Ferreira, S. M., de Barros Wanderley, M. R., das Dores Cruz, F., Gonçalves Brandão, S. M., Rigaud, V. O. C., Higuchi-dos-Santos, M. H., Hajjar, L. A., Kalil Filho, R., Hoff, P. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.049 · Cited by 507

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca, M. P., Olenchock, B. A., Salem, J.-E., Wiviott, S. D., Ederhy, S., Cohen, A., Stewart, G. C., Choueiri, T. K., Di Carli, M., Allenbach, Y., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034497 · Cited by 458

High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study

Shah, A. S. V., Griffiths, M., Lee, K. K., McAllister, D. A., Hunter, A. L., Ferry, A. V., Cruikshank, A., Reid, A., Stoddart, M., Strachan, F., et al. (2015) · BMJ · doi:10.1136/bmj.g7873 · Cited by 450

PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease)

Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.069 · Cited by 385

Heart Failure Stimulates Tumor Growth by Circulating Factors

Meijers, W. C., Maglione, M., Bakker, S. J. L., Oberhuber, R., Kieneker, L. M., de Jong, S., Haubner, B. J., Nagengast, W. B., Lyon, A. R., van der Vegt, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030816 · Cited by 385

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373

Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1957 · Cited by 368

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S. S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 356

N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study

Moe, G. W., Howlett, J., Januzzi, J. L., & Zowall, H. (2007) · Circulation · doi:10.1161/circulationaha.106.666255 · Cited by 325

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323

Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section

Januzzi, J. L., Filippatos, G., Nieminen, M., & Gheorghiade, M. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs191 · Cited by 314

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313

How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure

Daniels, L. B., Clopton, P., Bhalla, V., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.10.011 · Cited by 274

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer

Atkins, K. M., Rawal, B., Chaunzwa, T. L., Lamba, N., Bitterman, D. S., Williams, C. L., Kozono, D. E., Baldini, E. H., Chen, A. B., Nguyen, P. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.500 · Cited by 274

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., et al. (2015) · Heart · doi:10.1136/heartjnl-2015-307848 · Cited by 269

Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-Analysis

Michel, L., Mincu, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., & Totzeck, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1631 · Cited by 265

Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease

Caforio, A. L. P., Adler, Y., Agostini, C., Allanore, Y., Anastasakis, A., Arad, M., Böhm, M., Charron, P., Elliott, P. M., Eriksson, U., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx321 · Cited by 263

Clinical Use of High-Sensitivity Cardiac Troponin in Patients With Suspected Myocardial Infarction

Twerenbold, R., Boeddinghaus, J., Nestelberger, T., Wildi, K., Rubini Gimenez, M., Badertscher, P., & Mueller, C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.718 · Cited by 255

Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care

Wright, S. P., Doughty, R. N., Pearl, A., Gamble, G. D., Whalley, G. A., Walsh, H. J., Gordon, G., Bagg, W., Oxenham, H., Yandle, T., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.05.011 · Cited by 254

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

Sandri, M. T., Salvatici, M., Cardinale, D., Zorzino, L., Passerini, R., Lentati, P., Leon, M., Civelli, M., Martinelli, G., & Cipolla, C. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050153 · Cited by 250

N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department

Januzzi, J. L., Chen-Tournoux, A. A., Christenson, R. H., Doros, G., Hollander, J. E., Levy, P. D., Nagurney, J. T., Nowak, R. M., Pang, P. S., Patel, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.021 · Cited by 248

Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome

Chapman, A. R., Lee, K. K., McAllister, D. A., Cullen, L., Greenslade, J. H., Parsonage, W., Worster, A., Kavsak, P. A., Blankenberg, S., Neumann, J., et al. (2017) · JAMA · doi:10.1001/jama.2017.17488 · Cited by 246

Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer

Saiki, H., Petersen, I. A., Scott, C. G., Bailey, K. R., Dunlay, S. M., Finley, R. R., Ruddy, K. J., Yan, E., & Redfield, M. M. (2017) · Circulation · doi:10.1161/circulationaha.116.025434 · Cited by 243

High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis

Chin, C. W. L., Shah, A. S. V., McAllister, D. A., Joanna Cowell, S., Alam, S., Langrish, J. P., Strachan, F. E., Hunter, A. L., Maria Choy, A., Lang, C. C., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu189 · Cited by 233

High-sensitivity assays for troponin in patients with cardiac disease

Westermann, D., Neumann, J. T., Sörensen, N. A., & Blankenberg, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.48 · Cited by 222

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients

Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 207

Immune Checkpoint Inhibitor–Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution

Anquetil, C., Salem, J.-E., Lebrun-Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benveniste, O., Moslehi, J. J., & Allenbach, Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035898 · Cited by 199

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00231 · Cited by 198

State of the Art: Newer Biomarkers in Heart Failure

de Boer, R. A., Daniels, L. B., Maisel, A. S., & Januzzi, J. L. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.273 · Cited by 188

Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation–contraction coupling and reduces oxidative stress in adult rat cardiomyocytes

Timolati, F., Ott, D., Pentassuglia, L., Giraud, M.-N., Perriard, J.-C., Suter, T. M., & Zuppinger, C. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.08.002 · Cited by 178

Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab

Putt, M., Hahn, V. S., Januzzi, J. L., Sawaya, H., Sebag, I. A., Plana, J. C., Picard, M. H., Carver, J. R., Halpern, E. F., Kuter, I., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241232 · Cited by 178

0/1-Hour Triage Algorithm for Myocardial Infarction in Patients With Renal Dysfunction

Twerenbold, R., Badertscher, P., Boeddinghaus, J., Nestelberger, T., Wildi, K., Puelacher, C., Sabti, Z., Rubini Gimenez, M., Tschirky, S., du Fay de Lavallaz, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.028901 · Cited by 173

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

Zardavas, D., Suter, T. M., Van Veldhuisen, D. J., Steinseifer, J., Noe, J., Lauer, S., Al-Sakaff, N., Piccart-Gebhart, M. J., & de Azambuja, E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7916 · Cited by 164

Cardiovascular Toxicities Associated with Cancer Immunotherapies

Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 162

Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

Varricchi, G., Ameri, P., Cadeddu, C., Ghigo, A., Madonna, R., Marone, G., Mercurio, V., Monte, I., Novo, G., Parrella, P., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00167 · Cited by 158

Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction

Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & Keulenaer, G. W. D. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv132 · Cited by 156

Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea

Mueller, C. E., Laule-Kilian, K., Schindler, C. J. A., Klima, T. B., Frana, B., Rodríguez, D., Scholer, A., Christ, M., & Perruchoud, A. P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1081 · Cited by 147

Activity and Outcomes of a Cardio-Oncology Service in the United Kingdom—A Five-Year Experience

Pareek, N., Cevallos, J., Moliner, P., Shah, M., Tan, L. L., Chambers, V., Baksi, A. J., Khattar, R. S., Sharma, R., Rosen, S. D., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1292 · Cited by 145

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

Morris, P. G., Chen, C. C. L., Steingart, R. M., Fleisher, M., Lin, N., Moy, B., Come, S. E., Sugarman, S. M., Abbruzzi, A., Lehman, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1359 · Cited by 143

Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma

Grandin, E. W., Ky, B., Cornell, R. F., Carver, J. R., & Lenihan, D. J. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.11.008 · Cited by 130

Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer

Finkelman, B. S., Putt, M., Wang, T., Wang, L., Narayan, H., Domchek, S. M., DeMichele, A. M., Fox, K. R., Matro, J. M., Shah, P. D., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.019 · Cited by 124

ACE inhibition attenuates radiation-induced cardiopulmonary damage

van der Veen, S. J., Ghobadi, G., de Boer, R. A., Faber, H., Cannon, M. V., Nagle, P. W., Brandenburg, S., Langendijk, J. A., van Luijk, P., & Coppes, R. P. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.11.017 · Cited by 121

Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients

Rigaud, V. O. C., Ferreira, L. R. P., Ayub‐Ferreira, S. M., Ávila, M. S., Brandão, S. M. G., Cruz, F. D. D., dos Santos, M. H. H., Cruz, C. B. B. V., Lofrano‐Alves, M. S., Issa, V. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14355 · Cited by 119

Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart

Ganatra, S., Carver, J. R., Hayek, S. S., Ky, B., Leja, M. J., Lenihan, D. J., Lenneman, C. G., Mousavi, N., Park, J. H., Perales, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.049 · Cited by 118

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

Atrash, S., Tullos, A., Panozzo, S. B., Bhutani, M., van Rhee, F., Barlogie, B., & Usmani, S. Z. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2014.93 · Cited by 114

Novel heart failure biomarkers: why do we fail to exploit their potential?

Piek, A., Du, W., de Boer, R. A., & Silljé, H. H. W. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1460576 · Cited by 110

BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography

Skovgaard, D. C., Hasbak, P., & Kjær, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096736 · Cited by 108

Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment

Tan, L., & Lyon, A. R. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0641-z · Cited by 107

What to do when you question cardiac troponin values

Mair, J. M., Lindahl, B., Mueller, C. E., Giannitsis, E., Huber, K., Möckel, M., Plebani, M., Thygesen, K. A., & Jaffe, A. S. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617708973 · Cited by 101

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production

Du, W., Piek, A., Schouten, E. M., van de Kolk, C. W. A., Mueller, C. E., Mebazaa, A., Voors, A. A., de Boer, R. A., & Silljé, H. H. W. (2018) · Theranostics · doi:10.7150/thno.26055 · Cited by 100

Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study

Gulati, G., Heck, S. L., Røsjø, H. R., Ree, A. H., Hoffmann, P., Hagve, T., Norseth, J., Gravdehaug, B., Steine, K., Geisler, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006513 · Cited by 93

Diagnostic Evaluation of a High-Sensitivity Troponin I Point-of-Care Assay

Sörensen, N. A., Neumann, F., Ojeda, F., Giannitsis, E., Spanuth, E., Blankenberg, S., Westermann, D., & Zeller, T. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.307405 · Cited by 92

High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction

Boeddinghaus, J., Nestelberger, T., Twerenbold, R., Koechlin, L., Meier, M., Troester, V., Wussler, D. N., Badertscher, P., Wildi, K. S., Puelacher, C., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.300061 · Cited by 89

Abnormal NT‐pro‐BNP levels in asymptomatic long‐term survivors of childhood cancer treated with anthracyclines

Mavinkurve‐Groothuis, A. M. C., Loonen, J. J., Bellersen, L., Pourier, M. S., Feuth, T. B., Bökkerink, J. P. M., Hoogerbrugge, P. M., & Kapusta, L. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21913 · Cited by 87

ErbB2 signaling at the crossing between heart failure and cancer

Vermeulen, Z., Segers, V. F. M., & Keulenaer, G. W. D. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0576-z · Cited by 85

Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma

Demissei, B. G., Freedman, G. M., Feigenberg, S. J., Plastaras, J. P., Maity, A. M., Smith, A. M., McDonald, C., Sheline, K., Simone, C. B., Lin, L. L., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.11.013 · Cited by 84

2016 EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE. THE SIXTH JOINT TASK FORCE OF THE EUROPEAN SOCIETY OF CARDIOLOGY AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE (CONSTITUTED BY REPRESENTATIVES OF 10 SOCIETIES AND BY INVITED EXPERTS)

article, E. (2017) · Russian Cardiology Journal (Russian Cardiology Society) · Cited by 83

Comparison of Long-Term Outcome in Anthracycline-Related Versus Idiopathic Dilated Cardiomyopathy: A Single Centre Experience

Fornaro, A., Olivotto, I., Rigacci, L., Ciaccheri, M., Tomberli, B., Ferrantini, C., Coppini, R., Girolami, F., Mazzarotto, F., Chiostri, M., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1049 · Cited by 70

Long-Term Effect of Epirubicin on Incidence of Heart Failure in Women With Breast Cancer: Insight from a Randomized Clinical Trial

Banke, A., Fosbøl, E. L., Møller, J. E., Gislason, G., Andersen, M. J., Bernsdorf, M., Jensen, M., Schou, M., & Ejlertsen, B. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1168 · Cited by 70

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Adamson, P. D., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Cowans, N. J., Crim, C. C., Dixon, I. J., Martínez, F. J., Newby, D. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.051 · Cited by 70

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)

Ponde, N. F., Bradbury, I., Lambertini, M., Ewer, M. S., Campbell, C., Ameels, H., Zardavas, D., Cosimo, S. D., Baselga, J. M., Huober, J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4628-3 · Cited by 65

Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction

Boeddinghaus, J., Twerenbold, R., Nestelberger, T., Koechlin, L., Wussler, D. N., Meier, M., Troester, V., Zimmermann, T., Badertscher, P., Wildi, K. S., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.304725 · Cited by 65

In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer

Verma, S., McLeod, D., Batist, G., Robidoux, A., Martins, I., & Mackey, J. R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0278 · Cited by 56

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer

Yu, A. F., Manrique, C. R., Pun, S. C., Liu, J. E., Mara, E., Fleisher, M., Patil, S. N., Jones, L. W., Steingart, R. M., Hudis, C. A., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0321 · Cited by 56

Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea

Mueller, C., Scholer, A., & Laule-Kilian, K. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.04.023 · Cited by 54

The Role of Irradiated Heart and Left Ventricular Volumes in Heart Failure Occurrence After Childhood Cancer

Mansouri, I., Allodji, R. S., Hill, C., El‐Fayech, C., Pein, F. J. L., Diallo, S., Schwartz, B., Vu‐Bezin, G., Veres, C., Souchard, V., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1376 · Cited by 54

Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction

Beer, L. A., Kossenkov, A. V., Liu, Q., Prak, E. T. L., Domchek, S. M., Speicher, D. W., & Ky, B. (2016) · Circulation Research · doi:10.1161/circresaha.116.309004 · Cited by 52

Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy

de Azambuja, E., Ameye, L., Diaz, M., Vandenbossche, S., Aftimos, P. G., Hernández, S. B., Chao, S., Delhaye, F., Focan, C., Cornez, N., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.011 · Cited by 49

High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

Jones, M., O’Gorman, P., Kelly, C. M., Mahon, N., & Fitzgibbon, M. C. (2016) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563216650464 · Cited by 48

Biomonitoring and Biomarker-Guided Therapy

Maisel, A. S. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.032 · Cited by 47

Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy

Nadruz, W., West, E., Sengeløv, M., Grove, G. L., Santos, M., Groarke, J. D., Forman, D. E., Claggett, B. L., Skali, H., Nohria, A., et al. (2018) · Heart · doi:10.1136/heartjnl-2018-313234 · Cited by 44

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

Éderhy, S., Massard, C., Dufaître, G., Balheda, R., Meuleman, C., Gomez‐Roca, C., Izzedine, H., Cohen, A. A., & Soria, J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9546-8 · Cited by 41

Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review

Leerink, J. M., Verkleij, S. J., Feijen, E. A. M., Mavinkurve‐Groothuis, A. M. C., Pourier, M. S., Ylänen, K., Tissing, W. J. E., Louwerens, M., van den Heuvel‐Eibrink, M. M., Broeder, E. V. D., et al. (2018) · Heart · doi:10.1136/heartjnl-2018-313634 · Cited by 39

NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Gimeno, E., Gómez, M., González, J. R., Colet, J. C., Álvarez‐Larrán, A., Sánchez‐González, B., Balaguer, L. M., Domingo‐Doménech, E., García‐Pallarols, F., Pedro, C., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.01.018 · Cited by 38

The role of cardiac biomarkers in cardio-oncology

Riddell, E., & Lenihan, D. J. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.06.012 · Cited by 30

2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01806 · Cited by 77

Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?

Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76

Cardiovascular Magnetic Resonance from Fetal to Adult Life—Indications and Challenges: A State-of-the-Art Review

Moscatelli, S., Leo, I., Lisignoli, V., Boyle, S., Bucciarelli-Ducci, C., Secinaro, A., & Montanaro, C. (2023) · Children · doi:10.3390/children10050763 · Cited by 6